MetaCap

BioAge Labs (BIOA) vs Bright Minds Biosciences (DRUG)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

BioAge Labs (BIOA) has outperformed Bright Minds Biosciences (DRUG) over the past year, losing 50.5% versus a loss of 65.2%. Bright Minds Biosciences is the larger company by market cap ($201.2 million vs $196.7 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BIOA-50.52%DRUG-65.18%
+203%+61%-81%
Nov 21, 20251 yearNov 20, 2026
BIOA-79.62%DRUG+1572.13%
+7637%+3592%-452%
Sep 23, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BIOA versus DRUG key metrics
MetricBIOADRUG
Share price$4.28$20.40
Market cap$196.67M$201.23M
1-day change-9.13%-1.45%
YTD return-67.65%-73.86%
1-year return-50.52%-65.18%
5-year return—-7.27%
EPS (TTM)$-2.56$-2.05
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$8.99M—
Net income (latest FY)$-80.61M—
Operating margin-1031.46%—
Net margin-896.11%—
52-week high$25.96$123.75
52-week low$4.24$17.40
Distance from 52-week high-83.51%-83.52%
Analyst consensusbuystrong_buy
Avg. price target upside+572.43%+426.18%
Average volume740.06K173.24K
Shares outstanding45.95M9.86M
Employees6026
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • BIOA has outperformed DRUG by 14.7 percentage points over the past year.

About BioAge Labs

BIOA stock →

BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging.

Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees

About Bright Minds Biosciences

DRUG stock →

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies.

Health Care · Biotechnology: Pharmaceutical Preparations · 26 employees

BIOA vs DRUG FAQ

Which is bigger, BioAge Labs or Bright Minds Biosciences?

Bright Minds Biosciences (DRUG) is larger, with a market capitalization of $201.23M compared with $196.67M for BioAge Labs (BIOA).

Which stock has performed better over the past year, BIOA or DRUG?

BIOA returned -50.52% over the past 12 months, compared with -65.18% for DRUG (price return, excluding dividends). Past performance does not predict future results.

Are BioAge Labs and Bright Minds Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons